Mendus AB (“Mendus” publ; IMMU. ST), a biopharmaceutical firm with a focus on immunotherapies targeting tumors, has announced its participation in upcoming investor and industry conferences:
42nd Annual J.P. Morgan Healthcare Conference
- Location: San Francisco, USA
- Date: January 8-11, 2024
- Mendus management will be in San Francisco for business and investor meetings during the J.P. Morgan conference.
- J.P. Morgan Healthcare Conference
13th Annual LifeSci Partners Corporate Access Event
- Location: San Francisco, USA
- Date: January 8-10, 2024
- Mendus will participate in the LifeSci Corporate Access investor event.
- LifeSci Partners Corporate Access Event
Redeye Theme: Fight Cancer
- Location: Stockholm, Sweden
- Date: January 24, 2024
- Mendus CEO Erik Manting will present the company and join a discussion panel.
- Redeye Theme: Fight Cancer
For additional information, please contact: Erik Manting, CEO E-mail: ir.mendus.com
ABOUT MENDUS AB (PUBL) Mendus is committed to revolutionizing cancer treatment by addressing tumors and enhancing survival outcomes for cancer patients, all while maintaining their quality of life. Leveraging unparalleled expertise in allogeneic dendritic cell biology, Mendus is developing an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies that combine clinical efficacy with a safe profile. Headquartered in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. Mendus Website
